In addition, our data suggest that PIK3CA and RICTOR gene co-amplification may define a unique subset of patients with neuroendocrine tumors that will respond to AKT inhibitors, and could thus be used as an additional biomarker for treatment stratification. Here, AKT1 is linked to neuroendocrine neoplasm.